Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer
Parallel applications based on TROPION-Lung01 and TROPION-Breast01 Phase III trial results demonstrating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan significantly improved progression-free survival vs. chemotherapy in two types of cancer. The European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in two types of cancer. One MAA is for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who require systemic